CS MEDICA A/S, a Danish MedTech company specializing in pain management, autoimmune diseases, and stress-related disorders, is pleased to announce a new strategic partnership with Scan MedPartners, a US consultancy with a deep network and expertise in connecting Scandinavian medical technology companies with qualified high-value US partners in search of clinically proven, disruptive platform technologies, to improve outcomes for patients, providers and US payers. This collaboration represents a significant milestone in CS MEDICA's efforts to expand its presence in the United States, a core market for its innovative treatment portfolio.

CS MEDICA A/S has identified the US market as a crucial growth opportunity for its FDA-registered treatments with bioactive CBD. These treatments are designed to serve as perfect complements to both prescription-based options and non-regulated CBD products. Through this strategic partnership, CS MEDICA A/S aims to bring its safe and effective treatments with pharmaceutical grade, patent pending bioactive CBD to a broader patient population within the US healthcare sector.

Scan MedPartners will be pivotal in this expansion by leveraging its strong network of relationships with pharmaceutical and medical device industry portfolio decision-makers, specialty clinicians, hospital administrators, and associations across the US. With a deep understanding of the US healthcare landscape and a proven track record in securing high-value licensing agreements, Scan MedPartners will act as CS MEDICA's extended partner, ensuring that the company's treatments with bioactive CBD are recognized as valuable additions to the US market.

"We are excited to partner with Scan MedPartners," said CEO Lone Henriksen, CS MEDICA. "Their extensive expertise and strategic connections in the US healthcare market will help us navigate this important market's complexities and drive the adoption of our treatments with bioactive CBD among patients and providers alike."

Scan MedPartners assists primarily Scandinavian companies by connecting them with qualified US partners to validate their innovations in specialized therapeutic areas. By linking CS MEDICA A/S with qualified US partners and decision-makers, Scan MedPartners will facilitate the market positioning of its FDA-registered treatments with bioactive CBD and help secure distribution agreements with leading healthcare organizations.

"We see tremendous potential in CS MEDICA A/S's regulated treatments with bioactive CBD across multiple therapeutics fields, highlighting pain management, arthritis, anti-hair loss, wound care and allergies, to the benefit of millions of US patients in need of better, more patient effective products. We are eager to support CS MEDICA A/S on their sales growth journey, helping them accelerate their US market entry via US commercial partners," said Arne Madsen, President, Scan MedPartners. "Our deep market insights and robust relationships with key stakeholders will ensure that CS MEDICA A/S's products gain the traction needed to succeed in this competitive environment."
 

As part of the partnership, Scan MedPartners will assume comprehensive responsibilities, including regulatory support and commercialization activities, ensuring a seamless market entry for CS MEDICA A/S into the US healthcare sector.